Advertisement

Neurogenic inflammation in the pathogenesis of migraine

  • David W. Dodick
Chapter
Part of the Progress in Inflammation Research book series (PIR)

Abstract

Migraine is a prevalent and disabling disorder, which affects approximately 12% of the population of the United States [1]. The pathogenesis of the headache involves pain-sensitive cranial structures, possibly including the dura mater and large cerebral blood vessels and their trigeminal and cervical innervation [2]. The innervation of these structures is mediated primarily by the tentorial nerve, a branch of the ophthalmic nerve or first division of the trigeminal nerve, which also provides cutaneous innervation for the forehead and anterior vertex.

Keywords

Cluster Headache Dura Mater Trigeminal Ganglion Migraine Headache Migraine Without Aura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lipton RB, Stewart WF (1993) Migraine in the United States: epidemiology and health-care utilization. Neurology 43: 6–10Google Scholar
  2. 2.
    Goadsby PJ, Zagami AS, Lambert GA (1991) Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 31: 365–371PubMedCrossRefGoogle Scholar
  3. 3.
    Wolff HG (1963) Headache and other head pain. Oxford University Press, New YorkGoogle Scholar
  4. 4.
    Mayberg MR, Zervas NT, Moskowitz MA (1984) Trigeminal projections to supratentorial pial and durai blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comparative Neur 223: 46–56CrossRefGoogle Scholar
  5. 5.
    Mayberg MR, Langer RS, Zervas NT, Moskowitz MA (1981) Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science 213: 228–230PubMedCrossRefGoogle Scholar
  6. 6.
    Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA (1992) Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 48: 187–203PubMedCrossRefGoogle Scholar
  7. 7.
    Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma proteins occurs from blood vessels in the dura mater but not brain. J Neurosci 7: 4129–4136PubMedGoogle Scholar
  8. 8.
    Dimitriadou V, Buzzi MG, Moskowitz MA (1991) Trigeminal sensory fiber stimulation induces morphological changes in rat dura mater mast cells. Neuroscience 44: 97–112PubMedCrossRefGoogle Scholar
  9. 9.
    Edvinsson L, Hara H, Uddman R (1989) Retrograde tracing of nerve fibers to the rat middle cerebral artery with true blue: co-localization with different peptides. J Cerebral Blood Flow Metabol 9: 212–218CrossRefGoogle Scholar
  10. 10.
    Saria AL, Lundberg J, Skofitsch G et al (1983) Vascular leakage in various tissues induced by substance P, capsaicin, bradykinin, serotonin, histamine and antigen challenge. Naunyn Schmiedebergs Arch Parmacol 324: 212–218CrossRefGoogle Scholar
  11. 11.
    Cutrer FM, Limroth V, Waeber C et al (1997) New targets for antimigraine drug development. In: PJ Goadsby, SD Silberstein (eds): Headache. Butterworth-Heinemann, Boston, 59–72Google Scholar
  12. 12.
    Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23: 193–196PubMedCrossRefGoogle Scholar
  13. 13.
    Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann Neu-rol 33: 48–56Google Scholar
  14. 14.
    Edvinnson L, Goadsby PJ (1998) Neuropeptides in headache. Eur J Neurol 5: 329–341CrossRefGoogle Scholar
  15. 15.
    Cutrer FM, Moussaoui S, Garret C, Moskowitz MA (1995) The non-peptide neurokinin-1 antagonist, RPR 100893, decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience 64: 741–750PubMedCrossRefGoogle Scholar
  16. 16.
    Shepheard SL, Williamson DJ, Williams J et al (1995) Comparison of the effects of sumatriptan and the NK-1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacol 34: 255–261CrossRefGoogle Scholar
  17. 17.
    Shepheard SL, Williamson DJ, Hill RG, Hargreaves RJ (1993) The non-peptide NK-1 receptor antagonist RP 67580 blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol 108: 11–12PubMedCrossRefGoogle Scholar
  18. 18.
    Gitter BD, Bruns RF, Howbert JJ et al (1995) Pharmacological characterization of LY303870: a novel, potent, and selective nonpeptide substance P (neurokinin 1) receptor antagonist. J Pharmacol Exp Ther 275: 737–744PubMedGoogle Scholar
  19. 19.
    Goldstein DJ, Wang O, Saper JR (1997) Ineffectiveness of NK-1 antagonist in acute migraine: a crossover study. Cephalalgia 17: 785–790PubMedCrossRefGoogle Scholar
  20. 20.
    Connor HE, Bertin L, Gillies S et al (1998) Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine (abstract). Cephalalgia 18: 293CrossRefGoogle Scholar
  21. 21.
    Mantyh PW, DeMaster E, Malhotra A et al (1995) Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268: 1629–1632PubMedCrossRefGoogle Scholar
  22. 22.
    Goldstein DJ, Offen WW, Klein EG, Phebus LA (1999) Lanepitant, an NK-1 antagonist, in migraine prophylaxis (abstract). Cephalalgia 19: 377Google Scholar
  23. 23.
    Saria A (1999) The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 375: 51–60PubMedCrossRefGoogle Scholar
  24. 24.
    Zagami AS, Goadsby PJ, Edvinsson L (1990) Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16: 69–75PubMedCrossRefGoogle Scholar
  25. 25.
    Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28: 183–187PubMedCrossRefGoogle Scholar
  26. 26.
    Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in man and cat. Ann Neurol 33: 48–56PubMedCrossRefGoogle Scholar
  27. 27.
    Couch JR, Saper J, Meloche JP (1996) Treatment of migraine with BMS 180048: response at 2 hours. Headache 36: 523–530PubMedCrossRefGoogle Scholar
  28. 28.
    Knight YE, Edvinsson L, Goadsby PJ (1997). Blockade of release of CGRP after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288 (abstract). Cephalalgia 17: 248Google Scholar
  29. 29.
    Roon K, Diener HC, Ellis P et al (1997) CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical trials (abstract). Cephalalgia 17: 245Google Scholar
  30. 30.
    Fanciullaci M, Alessandri M, Fegini M et al (1995) Increases in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 60: 119–123CrossRefGoogle Scholar
  31. 31.
    Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 117: 427–434PubMedCrossRefGoogle Scholar
  32. 32.
    Ashina M, Bendtsen L, Jensen R et al (1999) Increased plasma levels of calcitonin gene-related peptide in migraine (abstract). Cephalalgia 19: 346Google Scholar
  33. 33.
    Tajti J, Uddman R, Møller F et al (1999) Neuronal messenger molecules and peptide receptors distribution in the human trigeminal ganglion (abstract). Cephalalgia 19: 392Google Scholar
  34. 34.
    Van Rossum D, Hanisch UK, Quirion R (1997) Neuroanatomical localization, pharmacologic characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 21: 649–678PubMedCrossRefGoogle Scholar
  35. 35.
    Jansen-Olesen I, Mortensen A, Edvinsson L (1996) Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibers and induces vasodilation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16: 310–316PubMedCrossRefGoogle Scholar
  36. 36.
    Moreno MJ, Abounader R, Lantin S et al (2000) CGRP-mediated dilations in human cerebral arteries are potently antagonized by BIBN4096BS, a selective CGRP receptor antagonist (abstract). Cephalalgia 20: 272–273Google Scholar
  37. 37.
    Lassen LH, Jacobson VB, Pedersen PA et al (1999) hCGRP-induced headache in migraineurs (abstract). Cephalalgia 19: 316Google Scholar
  38. 38.
    De Hoon JNJM, Pikkers P, Smits P et al (1999) Calcitonin gene-related peptide induces vasodilation by nitric oxide (abstract). Cephalalgia 19: 315Google Scholar
  39. 39.
    De Hoon JNJM, Pikkers P, Smits P et al (1999) Calcitonin gene-related peptide-induced vasodilation does not involve the activation of potassium channels in man (abstract). Cephalalgia 19: 397Google Scholar
  40. 40.
    Jansen-Olesen I, Edvinnson L (2000) Cephalic neurovascular transmitters and receptors. In: J Olesen, P Tfelt-Hansen, KMA Welch (eds): The headaches. Raven Press, New York, 87–98Google Scholar
  41. 41.
    Hasselblatt M, Köhler J, Volles E, Ehrenreich H (1999) Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine. Neuroreport 10: 423–425PubMedCrossRefGoogle Scholar
  42. 42.
    May A, Gijsman HJ, Wallnofer A et al (1996) Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67: 375–378PubMedCrossRefGoogle Scholar
  43. 43.
    Earl NL, McDonald SA, Lowy MT (1999) Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine (abstract). Cephalalgia 19: 357Google Scholar
  44. 44.
    Roon KI, Olesen J, Diener HC et al (2000) No acute antimigraine efficacy of CPP122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double blind, placebo-controlled clinical trials. Ann Neurol 47: 238–241PubMedCrossRefGoogle Scholar
  45. 45.
    Nissila M, Parkkola R, Sonninen P, Salonen R (1996) Intracerebral arteries and gadolinium enhancement in migraine without aura (abstract). Cephalalgia 16: 363Google Scholar
  46. 46.
    May A, Shepheard S, Wessing A et al (1998) Retinal plasma extravasation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. Brain 121: 1231–1237PubMedCrossRefGoogle Scholar
  47. 47.
    Pappagalo M, Szabo Z, Esposito G et al (1999) Imaging neurogenic inflammation in patients with migraine headaches (abstract). Neurology 52: A274–A275Google Scholar

Copyright information

© Springer Basel AG 2002

Authors and Affiliations

  • David W. Dodick
    • 1
  1. 1.Department of NeurologyMayo ClinicScottsdaleUSA

Personalised recommendations